Mylan Loses Bid To Toss Daiichi Benicar Patent

Law360, New York (September 10, 2010, 1:50 PM EDT) -- A federal appeals court has upheld an injunction banning Mylan Pharmaceuticals Inc. from making generic versions of Daiichi Sankyo Co. Ltd.'s Benicar and Azor until a patent for the hypertension drugs expires in 2016, ruling that the patent is not obvious.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit affirmed the 2009 decision finding the Japanese drug patent valid Thursday, rejecting claims from Mylan and Matrix Laboratories Ltd. that someone skilled in the art would have chosen to use the same...
To view the full article, register now.